Carcinogenesis Advance Access published online on February 3, 2005
Carcinogenesis, doi:10.1093/carcin/bgi038
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
* To whom correspondence should be addressed. Women with germline mutations in the breast cancer susceptibility gene BRCA1 are at increased risk of developing breast cancer. The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) has been shown to have clinical chemopreventive activity in premenopausal breast cancer patients. Since BRCA1 mutations are associated with early-onset breast cancer, usually before menopause, we hypothesized that 4-HPR may be an effective chemopreventive agent against breast tumors exhibiting BRCA1 mutations. The objective of this study was to determine the effectiveness and mechanisms of action of 4-HPR and its phenylretinamide analogues in BRCA1-mutated breast cancer cells. At clinically relevant doses, 4-HPR induced apoptosis in human (HCC1937) and murine (W0069, W525) BRCA1-mutated breast cancer cells. Among the various phenylretinamides tested, N-(2-carboxyphenyl)retinamide (2-CPR) and 3-CPR significantly inhibited the growth of HCC1937 cells; however, they were not as potent as 4-HPR in this respect. We also determined the mechanisms by which 4-HPR induces apoptosis in BRCA1-mutated breast cancer cells. The extent to which 4-HPR induced apoptosis in BRCA1-mutated cells correlated with increases in nitric oxide (NO) production and nitric oxide synthase (NOS) II and NOSIII expression. Use of a NOS inhibitor to block NO production suppressed the inhibitory effects of 4-HPR in all cell lines. These in vitro results suggest that 4-HPR may be an effective chemopreventive agent against breast tumors that exhibit BRCA1 mutations because of its ability to induce NO-mediated apoptosis in such tumors.
Received December 2, 2004
Revised January 13, 2005
Accepted January 26, 2005
MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION
N-(4-hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells
2 Genetics of Development and Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892, USA
3 Division of Cancer Treatment and Diagnostics, National Cancer Institute, Bethesda, MD 20892, USA
4 Division of Cancer Prevention, National Cancer Institute, Bethesda, MD 20892, USA
5 Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA
Ann-Marie Simeone, E-mail: amsimeon{at}mdanderson.org
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  U. Veronesi, L. Mariani, A. Decensi, F. Formelli, T. Camerini, R. Miceli, M. G. Di Mauro, A. Costa, E. Marubini, M. B. Sporn, et al. Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer Ann. Onc., July 1, 2006; 17(7): 1065 - 1071. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. I. Pritchard Fenretinide in the prevention of breast cancer in premenopausal women: fluke or fact? Ann. Onc., July 1, 2006; 17(7): 1035 - 1036. [Full Text] [PDF]
|
|
|
|
 |
|
 C.-X. Deng BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution Nucleic Acids Res., March 6, 2006; 34(5): 1416 - 1426. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Zanardi, D Serrano, A Argusti, M Barile, M Puntoni, and A Decensi Clinical trials with retinoids for breast cancer chemoprevention. Endocr. Relat. Cancer, March 1, 2006; 13(1): 51 - 68. [Abstract] [Full Text] [PDF]
|
|